Type of leukemia-Chronic Myeloid Leukemia (CML) Posts on Medivizor
Navigation Menu

Type of leukemia-Chronic Myeloid Leukemia (CML) Posts on Medivizor

Evaluating a method to predict the outcomes of patients with chronic myeloid leukemia treated with imatinib

Posted by on Mar 28, 2020 in Leukemia | 0 comments

In a nutshell The study tested whether the EUTOS long-term survival (ELTS) score is efficient to evaluate treatment response in patients with chronic myeloid leukemia (CML), treated with imatinib (Gleevec). The main finding was that ELTS could effectively predict treatment outcomes among such patients in the real world. Some background Initial...

Read More

Treating chronic myeloid leukemia with dasatinib

Posted by on Mar 13, 2020 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the long-term outcomes of dasatinib treatment for patients with chronic myeloid leukemia.   This study concluded that dasatinib is safe and provides positive long-term outcomes for these patients.   Some background Dasatinib (Sprycel) is a targeted therapy...

Read More

Is stopping nilotinib treatment safe in patients with chronic myelogenous leukemia that have achieved a stable response?

Posted by on Oct 12, 2019 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the safety and effectiveness of stopping nilotinib treatment in patients with chronic-phase chronic myelogenous leukemia.  This study concluded that stopping nilotinib after two years of consolidation treatment was safe and effective.  Some background...

Read More

Searching for patients with chronic myeloid leukemia to try a new combination of targeted treatments.

Posted by on Jun 29, 2019 in Leukemia | 0 comments

In a nutshell This study is searching for patients with chronic myeloid leukemia (CML) to try a new drug ruxolitinib (NSC-752295) with BCR-ABL Tyrosine Kinase Inhibitors. The main outcome that will be measured is the rate of significant reduction of the BCR-ABL marker. This trial is recruiting across the United States. The details BCR-ABL is a protein...

Read More

Looking for patients with Ph+ or BCR-ABL+ acute lymphoblastic leukemia to test a treatment combination

Posted by on Jun 14, 2019 in Leukemia | 0 comments

In a nutshell This phase 2 trial is evaluating the effectiveness of ponatinib (Iclusig) plus chemotherapy for patients with acute lymphoblastic leukemia (ALL) that is positive for the Philadelphia chromosome (Ph+) or the BCR-ABL gene (BCR-ABL+). The main outcome to be measured will be the number of patients who respond to treatment. This study is...

Read More